Clinical TrialMay 26, 2026, 08:04 AM
60 Degrees Pharma Ahead of Schedule in Babesiosis Trial Enrollment
AI Summary
60 Degrees Pharmaceuticals announced that the first patient for the 2026 tick season has been enrolled in its clinical trial (NCT06207370) evaluating tafenoquine for treating babesiosis. This enrollment puts the company approximately one month ahead of schedule, suggesting that minimum enrollment for an interim analysis could be achieved as soon as early July 2026. The randomized, double-blind, placebo-controlled trial, conducted at five sites in the Northeastern U.S., will enroll at least 24 patients before separate interim analyses on clinical symptom resolution and parasite clearance are conducted.
Key Highlights
- First patient of 2026 tick season enrolled in tafenoquine babesiosis clinical trial (NCT06207370).
- Enrollment is tracking approximately one month ahead of schedule.
- Minimum enrollment for interim analysis expected as soon as early July 2026.
- The study will enroll at least 24 patients prior to an interim analysis.
- Trial is randomized, double-blind, placebo-controlled, at five sites in the Northeastern U.S.
- Interim analyses will cover clinical symptom resolution and parasite clearance.
Price Impact
More from SXTP